ANNA-SHARI MELIN is a life sciences lawyer and German Rechtsanwältin. Her practice combines EU and German regulatory, compliance, and private equity/M&A knowledge. Her clients are pharmaceutical, biotechnology, medical device, food, cosmetic, and other consumer good companies.
Anna’s regulatory advice spans the product life cycle including analyses and strategy/risk assessments in relation to clinical trials, GMP compliance, early access programs and market access, pharmacovigilance, medicinal product shortages, recalls, the new medical devices regulations, pharmaceutical/device advertising, and related compliance. Anna has vast experience in multijurisdictional regulatory matters. She practices out of Munich and works closely with colleagues from Sidley’s Brussels, London, Geneva, and U.S. offices.
Anna co-leads Sidley’s benchmarking group for in-house pharmacovigilance lawyers (pvlegal) and regularly speaks on timely pharmacovigilance topics.
Anna has represented clients in matters before the European Commission, the European Medicines Agency, and numerous Member State authorities, including those in Germany. She has also been semi-seconded to numerous international pharmaceutical and biotech companies, becoming a right hand to senior in-house lawyers.
Prior to joining Sidley, Anna was an associate at international law firms in Brussels, where she was involved in pay-for-delay appeals in the EU and the UK. In addition, Anna has gained experience in German boutique firms as well as clerking for German higher regional court and lower court judges.